Skip to main content

Table 1 Demographic data

From: Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients

  Obese patients (n = 26) Non obese patients (n = 26) P value
Age, years 54.2 (16.8) 55.4 (16.0) 0.781
Male, n 18 21 0.337
TBW, kg 117 (23.3) 75.2 (13.3) <0.001
ABW, kg 87.7 (13.7) 71.0 (11.1) <0.001
IBW, kg 67.9 (13.1) 68.5 (10.5) 0.88
Height, in 67.6 (4.63) 68.5 (3.38) 0.393
Over IBW, % 1.77 (0.43) 1.1 (0.112) <0.001
BMI, kg/m2 41.0 (8.12) 24.9 (3.16) <0.001
APACHE II 20.3 (9.24) 18.7 (8.46) 0.524
Hospital mortality, n 5 4 0.714
Mechanical ventilation, n 24 26 0.149
Use of vasopressors, n 15 20 0.139
CVVH, n 9 9 1
Urine creatinine clearance (ml/min), n = 17 166 (62.7) 168.1 (59.1) 0.92
CVVH flow rate, ml/kg/h 21.3 (7.09) 21.9 (6.47) 0.86
Duration of vancomycin, days 6.88 (3.02) 6.5 (3.06) 0.415
Time from ICU admission to vancomycin initiation, days 2.73 (1.66) 2.53 (1.33) 0.647
Infection site
- Pneumonia
- Bacteremia
- SSTI
- Intraabdominal
- Unknown
16
2
2
3
3
19
0
3
2
2
0.375
0.149
0.638
0.638
0.638
Microbiology results
- MRSA
- MSSA
- Enterococcus
- Streptococcus spp.
- CoN Staphylococcus
- Other
6
2
0
2
4
12
7
3
1
3
3
9
0.749
0.638
0.313
0.638
0.685
0.397
  1. Results presented as mean (SD) unless stated otherwise. CVVH continuous venovenous hemofiltration, TBW total body weight, ABW adjust body weight, IBW ideal body weight, BMI body mass index, APACHE Acute Physiology and Chronic Health Evaluation, SSTI skin soft tissue infection, MRSA methicillin-resistant Staphylococcus aureus, MSSA, methicillin-sensitive Staphylococcus aureus